Prostate cancer is one of the most common cancers in men. Androgen deprivation therapy (ADT) is frequently used in patients with recurrent or metastatic prostate cancer. Although ADT improves survival in a subset of patients, these men develop profound hypogonadism resulting in decreased lean body mass, decreased muscle strength, decreased quality of life, increased fat mass, sexual dysfunction, and osteoporosis.1 Though less appreciated, these men also develop metabolic abnormalities. Within 3 months of initiation of ADT, these men develop significant hyperinsulinemia; however, there is no change in fasting glucose levels.2 To the contrary, long-term ADT is not only associated with insulin resistance, but also with hyperglycemia and metabolic syndrome.3,4 We have recently shown a significantly higher prevalence of insulin resistance, hyperglycemia, and metabolic syndrome in men with prostate cancer undergoing long-term ADT (ADT group) compared with the following 2 groups: (1) men with prostate cancer who had undergone local surgery and/or radiation but were not androgen deprived (and were eugonadal) (non-ADT group) and (2) age-matched healthy eugonadal men (controls).3,4 These findings suggest that hypogonadism may be the inciting factor in the development of these complications, though prospective studies are needed to confirm these findings. These complications of ADT are surfacing at a time when cardiovascular diseases have become the single most common cause of mortality in this patient population.5 Although it is known that men receiving ADT have metabolic abnormalities, it is unknown whether the duration of ADT is related to the severity of these perturbations.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Correlation between the duration of androgen deprivation therapy, (ADT) and waist circumference (R2 = 0.53, P<.01) (A), fasting glucose (FPG) (R2 = 0.23, P = .04) (B); fasting insulin (R2 = 0.14, P = .13) (C), and homeostatic model assessment for insulin resistance (HOMAIR) (R2 = 0.25; P = .03) (D). To convert waist circumference to centimeters, multiply by 2.54; to convert glucose to millimoles per liter, multiply by 0.0555; to convert insulin to picomoles per liter, multiply by 6.945.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.